Autopsy report · NCT01135524
Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase
Cause of deathStaffing, sites or logistics
“This study was terminated early for administrative reasons.”
Life of this trial
- Registered 6 years 2 months after it had already started.
- Ran for about 1 year 4 months before it stopped.
- 196 participants enrolled.
- Results were posted on the registry 5 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Purdue Pharma LP
- Sponsor type
- Industry
- Conditions
- Osteoarthritis
- Interventions
- Buprenorphine transdermal patch; Buprenorphine transdermal patch; Buprenorphine transdermal patch
- Participants
- 196
- Sites
- 89
- Countries
- United States
Trials that died the same way
- Measuring Relative Afferent Pupillary Defect
“The study was terminated early for administrative reasons.” - An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections
“Study was prematurely terminated due to administrative and strategic reasons” - Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)
“The study was terminated due to administrative, non-safety related reasons.” - Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
“Study was terminated due to administrative reasons” - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
“The study was terminated early due to company decision.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.